EWTX
What one share of Edgewise Therapeutics holds
Pharmaceutical Preparations
At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases.
Edgewise Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.85 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.49 |
| Cash and investments | $0.67 |
| Book value | $4.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$23.17 | $0.27 | −$20.08 | — | −$33.11 |
| 2021 | — | −$1.14 | $0.02 | −$0.91 | — | $5.54 |
| 2022 | — | −$1.26 | $0.10 | −$1.09 | — | $5.48 |
| 2023 | — | −$1.57 | $0.09 | −$1.53 | — | $4.53 |
| 2024 | — | −$1.45 | $0.01 | −$1.19 | — | $4.84 |
| 2025 | — | −$1.63 | $0.00 | −$1.40 | — | $4.92 |